Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers

Trial Profile

Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG 594 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 14 Apr 2020 Status changed from recruiting to suspended, to protect the safety and health of clinical study participants and healthcare professionals as well as reduce the burden on the healthcare systems fighting COVID-19.
    • 09 May 2019 According to a Cytokinetics media release, the company expects the conduct of this study to continue throughout 2019.
    • 20 Feb 2019 Status changed from planning to recruiting, according to a Cytokinetics media release.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top